POS1266 A PHASE IA, RANDOMIZED STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF RO7303509, AN ANTI-TGFΒ3 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

Abstract

BackgroundTransforming growth factor beta (TGFβ) cytokines (TGFβ1, TGFβ2, and TGFβ3) play critical roles in tissue fibrosis.[1] However, treating fibrotic diseases with systemic pan-TGFβ inhibitors has demonstrated unacceptable toxicities.[2,3] In human...